|
Torasemide
drug data and news
Torasemide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Torasemide
|
| Brand Names/Synonyms |
AC 4464; CCRIS 6736; Demadex; JDL 464; Luprac; TORSEMIDE; Torasemida [Inn-Spanish]; Torasemide; Torasemidum [Inn-Latin]; Torsemide; Torsemide [Usan] |
| Indication |
For the treatment of hypertension, edema induced by congestive heart failure or renal disease and ascites assocated with hepatic disease |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Torasemide, a monosulfonamyl loop diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Torasemide is used alone or with atenolol in the management of hypertension and edema. Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na+/K+/2CI--carrier system. |
| Mechanism Of Action |
Torasemide acts on the Na+/K+/2Cl- co-transporter. It inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism |
Torasemide News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
LIQUID; TABLET |
| Drug_Category |
Diuretics; Antihypertensive Agents; ATC:C03CA04 |
| Absorption |
Bioavailability is ~80%, serum concentration peaks after ~1 hour |
| Interactions |
Not Available |
| Toxicity |
LD50 = 5 g/kg (rat, oral), 500 mg/kg (rat, intravenous). Side effects include dizziness, headache, nausea and vomiting. |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
1-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonyl-3-propan-2-yl-urea |
| Chemical Formula |
C16H20N4O3S Not Available |
| Molecular Weight |
348.421 g/mol |
| Smiles String |
CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C |
| Melting Point |
163-164 oC (decomposition) |
| Water Solubility |
water soluble |
| State |
Solid |
| LogP/Hphobicity |
2.404 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Primarily hepatic (80%) |
| Half Life |
3.5 hours |
| Protein Binding [%] |
~75-98% |
| RxList Link |
RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.rxlist.com/cgi/generic/demadex.htm |
| Drug Type |
Approved Drug |
| Accession No |
APRD00217 |
| CAS Registry Number |
56211-40-6 |
| KEGG Compound ID |
C07152 |
| PubChem ID |
SID:9361 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2129094
|
|
|
